Futura Medical Résultats passés
Passé contrôle des critères 0/6
Futura Medical has been growing earnings at an average annual rate of 6.8%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been growing at an average rate of 93.3% per year.
Informations clés
6.8%
Taux de croissance des bénéfices
19.2%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 14.1% |
| Taux de croissance des recettes | 93.3% |
| Rendement des fonds propres | -48.1% |
| Marge nette | -44.7% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Need To Know: Analysts Are Much More Bullish On Futura Medical plc (LON:FUM)
Sep 13
We Think Futura Medical (LON:FUM) Can Easily Afford To Drive Business Growth
Apr 17Here's Why We're Not At All Concerned With Futura Medical's (LON:FUM) Cash Burn Situation
Jan 05Is Futura Medical (LON:FUM) In A Good Position To Invest In Growth?
Jul 28We Think Futura Medical (LON:FUM) Needs To Drive Business Growth Carefully
Mar 18We're Keeping An Eye On Futura Medical's (LON:FUM) Cash Burn Rate
Sep 25Here's Why We're Not Too Worried About Futura Medical's (LON:FUM) Cash Burn Situation
May 10We're Interested To See How Futura Medical (LON:FUM) Uses Its Cash Hoard To Grow
Jan 10What We Learned About Futura Medical's (LON:FUM) CEO Compensation
Dec 21
Ventilation des recettes et des dépenses
Comment Futura Medical gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 8 | -4 | 8 | 2 |
| 31 Mar 24 | 6 | -5 | 7 | 2 |
| 31 Dec 23 | 3 | -7 | 7 | 2 |
| 30 Sep 23 | 2 | -6 | 5 | 3 |
| 30 Jun 23 | 2 | -5 | 4 | 3 |
| 31 Mar 23 | 1 | -5 | 3 | 4 |
| 31 Dec 22 | 0 | -6 | 3 | 4 |
| 30 Sep 22 | 0 | -6 | 3 | 4 |
| 30 Jun 22 | 0 | -6 | 2 | 4 |
| 31 Mar 22 | 0 | -5 | 2 | 4 |
| 31 Dec 21 | 0 | -5 | 2 | 4 |
| 30 Sep 21 | 0 | -4 | 2 | 3 |
| 30 Jun 21 | 0 | -3 | 1 | 2 |
| 31 Mar 21 | 0 | -3 | 1 | 2 |
| 31 Dec 20 | 0 | -2 | 1 | 2 |
| 30 Sep 20 | 0 | -4 | 1 | 4 |
| 30 Jun 20 | 0 | -6 | 1 | 6 |
| 31 Mar 20 | 0 | -7 | 1 | 8 |
| 31 Dec 19 | 0 | -9 | 1 | 10 |
| 30 Sep 19 | 0 | -9 | 1 | 10 |
| 30 Jun 19 | 0 | -8 | 1 | 9 |
| 31 Mar 19 | 0 | -7 | 1 | 8 |
| 31 Dec 18 | 0 | -6 | 1 | 6 |
| 30 Sep 18 | 0 | -5 | 1 | 5 |
| 30 Jun 18 | 0 | -4 | 1 | 4 |
| 31 Mar 18 | 0 | -4 | 1 | 4 |
| 31 Dec 17 | 0 | -4 | 1 | 4 |
| 30 Sep 17 | 0 | -4 | 1 | 4 |
| 30 Jun 17 | 0 | -3 | 1 | 3 |
| 31 Mar 17 | 0 | -4 | 1 | 3 |
| 31 Dec 16 | 0 | -4 | 1 | 4 |
| 30 Sep 16 | 0 | -4 | 1 | 4 |
| 30 Jun 16 | 0 | -5 | 1 | 4 |
| 31 Mar 16 | 0 | -5 | 1 | 4 |
| 31 Dec 15 | 0 | -5 | 1 | 5 |
| 30 Sep 15 | 0 | -5 | 1 | 4 |
| 30 Jun 15 | 0 | -4 | 1 | 4 |
| 31 Mar 15 | 0 | -4 | 1 | 3 |
| 31 Dec 14 | 0 | -3 | 1 | 2 |
| 30 Sep 14 | 0 | -3 | 1 | 2 |
| 30 Jun 14 | 0 | -3 | 1 | 2 |
| 31 Mar 14 | 0 | -2 | 1 | 2 |
| 31 Dec 13 | 0 | -2 | 1 | 2 |
Des revenus de qualité: FUM is currently unprofitable.
Augmentation de la marge bénéficiaire: FUM is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: FUM is unprofitable, but has reduced losses over the past 5 years at a rate of 6.8% per year.
Accélération de la croissance: Unable to compare FUM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: FUM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.5%).
Rendement des fonds propres
ROE élevé: FUM has a negative Return on Equity (-48.05%), as it is currently unprofitable.